First clinical assessment of a prototype assay to detect the enzymatic activity of β-lactamase as a marker for pulmonary tuberculosis

Diagn Microbiol Infect Dis. 2020 Jun;97(2):115026. doi: 10.1016/j.diagmicrobio.2020.115026. Epub 2020 Feb 19.

Abstract

The objective was to evaluate the sensitivity and specificity of a novel prototype test, TB REaD™, a reporter enzyme fluorescence-based assay, for pulmonary tuberculosis and to determine the optimal threshold for test positivity. This blinded, prospective study enrolled 250 patients, of which 23.2% were Mycobacterium tuberculosis complex (MTB) culture-positive. At the manufacturer-set threshold, sensitivity of the assay was 93.1% (95% confidence interval [CI] 83.3-98.1) and specificity was 8.9% (95% CI 5.2-13.8). The highest accuracy was seen at a higher threshold: sensitivity 58.6% (95% CI 44.9-71.4), specificity 59.4% (95% CI 52.1%-66.4%), with sensitivity by smear status being 40.0% (95% CI 21.1-61.3) for smear-negative and 72.7% (95% CI 54.5-86.7) for smear-positive. This study demonstrated limited accuracy of the TB REaD™ prototype for detection of pulmonary TB. Further improvements are necessary, potentially exploring probes that are more specific to MTB.

Keywords: Diagnosis; TB REaD™; Tuberculosis; β-Lactamase.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Biomarkers / analysis
  • Clinical Enzyme Tests / methods*
  • Female
  • Fluorescence
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / enzymology*
  • Point-of-Care Systems
  • Prospective Studies
  • Reagent Kits, Diagnostic
  • Sensitivity and Specificity
  • Sputum / microbiology*
  • Tuberculosis, Pulmonary / diagnosis*
  • beta-Lactamases / analysis*
  • beta-Lactamases / metabolism

Substances

  • Biomarkers
  • Reagent Kits, Diagnostic
  • beta-Lactamases